

PUBLICATIONS - DR ARTHUR CLEMENTS

Lam T, Chan MMK, Sweeting AN, DeSousa S, **Clements A**, Carlino M, Mcneil C, Long GV, Tonks K, Chua E, Kefford RF, Chipps D. Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series.

Intern Med J. 2015 May 26

Anforth R, Carlos G, Eiris N, **Clements A**, Fernandez-Penas P. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma on dexamethasone.

Med J Aust. 2015; 203 (1): 41-42

Carlos G, Anforth R, **Clements A**, Menzies A, Carlino M, Chou S, Fernandez Penas. Cutaneous Toxicities of BRAF inhibitors, alone and in combination with MEK inhibitors for metastatic melanoma.

JAMA Dermatol. 2015 Jul 22

Carlos G, Anforth R, **Clements A**, Chou S, Fernandez-Penas P. A Case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

Melanoma Res. 2015 Jun; 25 (3): 265-8

Chan MMK, Kefford RF, **Clements A**, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody Pembrolizumab in metastatic melanoma.

J Immunotherapy. 2015 Jan; 38 (1): 37-9

Lee CI, Menzies AM, Haydu LE, Azer M, **Clements A**, Kefford RF, Long GV. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Melanoma Res. 2014 Oct; 24 (5): 468-74

Lyle M, Menzies AM, **Clements A**, Chan MMK, Lee, J, Carlino M, Kefford RF, Long GV. Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

J Clin Oncol. 32:5s, 2014 (suppl; abstr 9077)

Chan MMK, Haydu LE, Menzies AM, Azer MWF, Klein O, Lyle M, **Clements A**, Guminski A, Kefford RF, Long GV. 'The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition'.

Cancer. 2014 Oct 15; 120 (20): 3142-53. doi: 10.1002/cncr.28851

Epub 2014 Jul 1

Anforth R, Carlos G, **Clements A**, Kefford RF, Fernandez-Penas P. 'Cutaneous Adverse Events in Patients treated with BRAF Inhibitor Based Therapies for Metastatic Melanoma for longer than 52 Weeks.

Br J Dermatology. 2015 Jan; 172 (1): 239-43. doi: 10.1111/bjd.13200

Epub 2014 Nov 21

Pulvirenti T, Long GV, **Clements A**, Forstner D, Hong A, Kefford R, Wang T. Acute Radiation Skin Toxicity Associated with BRAF inhibitors. *J Clin Oncol*. 2014 May 27. pii: JCO.2013.49.0565. [Epub ahead of print]

Del Vecchio M, Hersh EM, Brown MP, **Clements A**, Loquai C, Ferrucci PF, Robert C, Li M, Elias I, Renschier MF, Hauschild A. A phase III trial of nab-paclitaxel vs dacarbazine in chemotherapy-naive patients (pts) with metastatic melanoma: analysis of peripheral neuropathy. *J Clin Oncol*. 31, 2013 (suppl; abstr e20025)

Klein O, Ribas A, Chmielowski B, Walker G, **Clements A**, Long GV, Kefford K. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. *J Clin Oncol*. 2013; 31: e215-7

Chan MM, Haydu L, Menzies AM, Azer M, Klein O, Lyle M, **Clements A**, Guminski A, Kefford RF, Long GV. Continued BRAF inhibition for progressive melanoma. *The Lancet Oncology* 2013; 14 (10): 928. doi:10.1016/S1470-2045(13)70217-1

Klein O, **Clements A**, Menzies AM, O'Toole S, Kefford R, Long GV. BRAF inhibitor activity in V600R metastatic melanoma – Response. *Eur J Cancer* 2013; 49: 1073-9

Klein O, **Clements A**, Menzies A, Kefford R, Long GV. 'BRAF inhibitor activity in V600R metastatic melanoma.' *Eur J Cancer* 2013; 49: 1797-8

Anforth R, Blumetti TC, **Clements A**, Kefford R, Long GV, Fernandez-Peñas P. Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. *Br J Dermatol*. 2013 Jul 20. doi: 10.1111/bjd.12519. [Epub ahead of print]

Anforth R, Carlos G, Long GV, Kefford R, **Clements A**, Sharma R, Chou S, Fernandez-Peñas P. Cutaneous Toxicities of MAPK inhibitors: RAF inhibitors, MEK inhibitors and Combination therapy. A case series from an Australian Institution. *Poster presentation at 8th World Melanoma Congress July 2013*

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, **Clements A**, Long GV, Fernandez-Peñas P. Acneiform Eruptions: A Common Cutaneous Toxicity of the MEK Inhibitor Trametinib. *Australasian Journal of Dermatology* 2014 Nov; 55(4): 250-4

De Souza P, Begbie S, Hovey L, Rashid P, Aslan P, Malouf D, Awad N, **Clements A**, Hadley A, Galettis P, O'Malley L, Melbourne W, Johnson L, Tran K, Lynch W. Phase II Trial of Intravesical Gemcitabine and Biomarker Evaluation in Patients with Superficial Urothelial Carcinoma of the Bladder. *World J. Cancer Res*. 1,131-137 (2013)

Gao B, Yeap SHO, **Clements A**, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. *J Clin Oncol.* 2012 Nov 10; 30 (32): 4017-25. doi:10.1200/J Clin Onc.2012.43.5362

Lee CI, Menzies AM, Haydu L, **Clements A**, Kefford R, Long GV. Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM). *J Clin Oncol.* 2012; 30 (15_suppl): e19011

Menzies A, Lee C, Haydu L, Azer M, **Clements A**, Kefford R, et al. (2012) Clinical correlates and management of pyrexia in patients (pts) treated with dabrafenib combined with trametinib (CombiDT) for V600 BRAF-mutant metastatic melanoma. *Pigment Cell Melanoma Res* 25: 873 (abstract)

Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, Gurney H. 'Metformin in preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome'. *Annals of Oncology* Vol. 22 issue 12 December 2011. p. 2556-2560

Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA III, Kim KB, **Clements A**, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. 'Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)'. *J Clin Oncol.* 29, 2011 (suppl; abstr 8503)